

Product datasheet for **KN402922**

CD19 Human Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	CD19
Locus ID:	930
Components:	<p>KN402922G1, CD19 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002), Target Sequence: TCCTCACCCCATGGAAGTC</p> <p>KN402922G2, CD19 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002), Target Sequence: TTCACCACTAGAGGTTCTCTC</p> <p>KN402922D, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP: The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.</p>

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
 CATCGCCAC AGTCCCGAG AAGTTGGGG GAGGGTTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
 CGGGGTAAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCG CTTTTCCCG AGGGTGGGG AGAACCCTAT
 ATAAGTGAC TAGTCGCCG GAACGTTCT TTTCCGAACG GGTTCGCCG CAGAACACAG GTAAGTGCCG
 TGTGTGGTTC CCGCGGGCCT GGCCTCTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTCCACCTG
 GCTGCAGTAC GTGATTCTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGGG AGAGTTCGAG GCCTTGCGCT
 TAAGGAGCCC CTCGCCTCG TGCTTGAGTT GAGGCCTGGC CTGGGGCTG GGGCCGCCG GTGCGAATCT
 GGTGGCACCT TCGCGCCTGT CTCGCTGCT TCGATAAGTC TCTAGCCATT TAAAATTTTT GATGACCTGC
 TGCGACGCT TTTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT
 TTTGGGGCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCGAGGCGG GGCCTGCGAG
 CGCGGCCACC GAGAATCGGA CGGGGGTAGT CTCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
 GCCGTGTATC GCCCCGCCCT GGGCGGCAAG GCTGGCCCG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
 CCGCTTCCCG GCCCTGCTG AGGGAGCTCA AAATGGAGGA CGCGGCCTC GGGAGAGCGG GCGGGTGAGT
 CACCCACACA AAGGAAAAG GCCTTCCGT CTCAGCCGT CGTTTCATGT GACTCCACGG AGTACCGGGC
 GCCGTCCAG CACCTCGATT AGTTCTCGAG CTTTTGAGT ACGTCTGCT TAGGTTGGGG GGAGGGGTTT
 TATGCGATGG AGTTTCCCA CACTGAGTGG GTGGAGACTG AAGTTAGGCC AGCTTGGCAC TTGATGTAAT
 TCTCCTTGA ATTTGCCCT TTTGAGTTG GATCTTGGT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
 TTTTTTCTT CCATTTTCAGG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
 TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTGAGC TGGTGGGCGG CGGAGAGGGC ACCCCGAGC
 AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA
 CGTGATGGG TACGGCTTCT ACCACTTCGG CACCTACCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
 ATCAACAACG GCGGCTACAC CAACACCCG ATCGAGAAGT ACGAGGACGG CGGCGTGCT CACGTGAGCT
 TCAGCTACCG CTACGAGGCC GGCCCGTGA TCGGCGACT CAAGGTGATG GGCACCGGCT TCCCGGAGGA
 CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGGCGAT



```

AACGATCTGG ATGGCAGCTT CACCCGCACC TTCAGCCTGC GCGACGGCGG CTACTIONACAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCCA TGTTGCCTT
CCGCCCGGTG GAGGAGGATC ACAGCAACAC CGAGCTGGGC ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTACTIONCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGCC CACGGTGGC CTCGCCACCC GCGACGACGT
CCCCAGGGCC GTACGCACCC TCGCCGCCG GTTCGCCGAC TACCCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAACTCT TCCTCACGGC CGTCGGGCTC GACATCGGCA
AGGTGTGGGT CGCGGACGAC GCGCCCGCGG TGGCGGTCTG GACCACGCCG GAGAGCGTCG AAGCGGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGCCG TGGCCCGCA GCAACAGATG
GAAGGCCTCC TGGCGCCGCA CCGGCCAAG GAGCCCGCT GGTTCCTGGC CACCGTCGGC GTCTCGCCG
ACCACCAGGG CAAGGTCTG GGCAGCGCCG TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTTC CTGGAGACCT CCGCGCCCG CAACCTCCC TTCTACGAGC GGCTCGGCTT CACCGTCACC
GCCGACGTCG AGGTGCCGA AGGACCGCG ACCTGGTCA TGACCCGAA GCCCGGTGCC TGAAACTTGT
TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAAG CATTTTTTTC
ACTGCATTCT AGTTGTGGT TGTCCAACT CATCAATGTA TCTTAATAAC TTCGTATAAT GTATGTATA CGAAGTTAT

```


Disclaimer:

These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

RefSeq:

[NM_001178098](#), [NM_001770](#)

UniProt ID:

[P15391](#)

Synonyms:

B4; CVID3

Summary:

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Product images:

